Narrow search
Showing 1 - 10 of 22,221
Cover Image
RU 486 : the pill that could end the abortion wars and why American women don't have it
Lader, Lawrence - 1991 - 1. print.
Persistent link: https://www.econbiz.de/10004127060
Cover Image
Acceptable risks
Kwitny, Jonathan - 1992
Persistent link: https://www.econbiz.de/10004154287
Cover Image
The regulation of pharmaceuticals : balancing the benefits and risks
Grabowski, Henry G.; Vernon, John M. - 1983
Persistent link: https://www.econbiz.de/10004778249
Cover Image
Predatory pricing
Phlips, Louis - 1987
Persistent link: https://www.econbiz.de/10004620572
Cover Image
Prices, wages and business cycles : a dynamic theory
Klein, Burton Harold - 1984
Persistent link: https://www.econbiz.de/10004584021
Cover Image
Generics substitution, bioequivalence standards, and oversight of international pharmaceutical producers: Complex issues facing the FDA
Mathur, Aparna; Bate, Roger - American Enterprise Institute - 2015
In this paper, the authors document the complex issues facing the FDA in assessing the quality of generic drugs. They conclude that increased transparency as well as the updating of FDA bioequivalence standards may be important to overcome some of these challenges.
Persistent link: https://www.econbiz.de/10011273206
Cover Image
Drug Policy 1986
eSocialSciences - 2005
Drug Policy of 1986
Persistent link: https://www.econbiz.de/10009323735
Cover Image
Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation
Berndt, Ernst; Aitken, Murray - In: International Journal of the Economics of Business 18 (2011) 2, pp. 177-201
find that once one incorporates substitution to lower priced generics following patent expiration, average price per …We examine market share and price trends in the quarter century since the 1984 Waxman-Hatch legislation. The generic …. Whereas in 1994 the generic price index fell from 100 to 65 in the 24 months following initial generic entry, in 2009 the …
Persistent link: https://www.econbiz.de/10009275875
Cover Image
Competition and the Reference Pricing Scheme for pharmaceuticals
Ghislandi, Simone - In: Journal of Health Economics 30 (2011) 6, pp. 1137-1149
By introducing n (>1) firms with infinite cross-price elasticity (i.e. generic drugs), we explore the effects of … the reference price (R) does not depend on the price of the branded product. When generics collude, the way R is designed …
Persistent link: https://www.econbiz.de/10010870801
Cover Image
Tendering and decision-making: a case on pharmaceutical products
Dankers, Sven; Vieira, Rui - In: World Review of Entrepreneurship, Management and … 8 (2012) 2, pp. 236-263
In order to contain expenditures for pharmaceuticals, the latest healthcare reforms have focused on decentralising …
Persistent link: https://www.econbiz.de/10010670125